Breaking: Abcam to be Acquired by Danaher; Setback for NovoCure
- August 28th, 2023
- 531 views
Abcam plc (Nasdaq: ABCM) has agreed to be acquired by Danaher Corporation (NYSE: DHR) for $24.00 per share in cash.
The transaction has received unanimous approval from both Abcam's and Danaher's Boards of Directors.
In pre-market, $ABCM is trading at $23.45, up $0.09 (+0.39%), while $DHR is at $254.75, showing a decline of $0.78 (-0.31%).
In another development, NovoCure Limited (Nasdaq: NVCR) announced that its phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 clinical trial evaluating Tumor Treating Fields (TTFields) alongside paclitaxel in patients with platinum-resistant ovarian cancer has not met its primary endpoint of overall survival (OS) in the final analysis.
$NVCR is currently trading at $18.00 in pre-market, down $11.77 (-39.54%) following the announcement
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Treasury Targets Family Members and Associates of Maduro Regime
December 20th, 2025Herbal Works Inc. Supports President Trump's Order Easing Restriction on Cannabis
December 18th, 2025Herbal Works Inc. Plans on Expansion of Product Line in 2026
December 18th, 2025December 17th, 2025Crown Equity Holdings Inc. Announces Changes to Board of Directors
December 16th, 2025
Member Login